Cited in PMC for PubMed (Select 33463590) - PMC

Select item 110396011.

Efficacy, Safety and Immunogenicity of Sun’s Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study

Asim K. Ghosh, Usha S. Nikumbh, Chaitanya K. Shukla, Rohit S. Laul, Abhishek Dixit, Santosh K. Mahapatra, Sameera Nayak, Urmil M. Shah, Sandeep Parwal, Narendran Venkatapathy, Natasha Radhakrishnan, Anup Kelgaonkar, Sandeep Saxena, Divyansh Mishra, Vivek Pravin Dave, Perwez Khan, Manojkumar R. Saswade, Malli S. Shantilal, Kim Ramasamy, Smitha Sreekanta, Mandodari Rajurkar, Maulik Doshi, Sapan Behera, Piyush Patel, Shilpi Dhawan, Lalit Lakhwani

Ophthalmol Ther. 2024 May; 13(5): 1369–1382. Published online 2024 Mar 26. doi: 10.1007/s40123-024-00883-5

PMCID:: PMC11039601

Article PDF–625K

Select item 107781312.

Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study)

Somnath Chakraborty, Jay Umed Sheth

Clin Ophthalmol. 2024; 18: 61–68. Published online 2024 Jan 6. doi: 10.2147/OPTH.S443104

PMCID:: PMC10778131

Article PDF–369K

Select item 104019083.

Anti‐vascular endothelial growth factor biosimilars for macular degeneration

Cochrane Database Syst Rev. 2023; 2023(8): CD015804. Published online 2023 Aug 4. doi: 10.1002/14651858.CD015804

PMCID:: PMC10401908

Article PDF–217K

Select item 102289224.

Commentary: Biosimilars in the treatment of retinopathy of prematurity

Tanvi Soni, Piyush Kohli

Indian J Ophthalmol. 2023 Feb; 71(2): 416–417. Published online 2023 Feb 2. doi: 10.4103/ijo.IJO_2254_22

PMCID:: PMC10228922

Article PDF–549K

Select item 100973985.

Debdulal Chakraborty, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Saptorshi Majumdar, Ranabir Bhattacharya, Ritobroto Maitra

Clin Ophthalmol. 2023; 17: 1067–1076. Published online 2023 Apr 8. doi: 10.2147/OPTH.S407219

PMCID:: PMC10097398

Article PDF–2.2M

Select item 96627296.

Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial

Chang Ki Yoon, Jaeryung Oh, Kunho Bae, Un Chul Park, Kyung-Sang Yu, Hyeong Gon Yu

PLoS One. 2022; 17(11): e0275611. Published online 2022 Nov 14. doi: 10.1371/journal.pone.0275611

PMCID:: PMC9662729

Article PDF–1.6M

Select item 91516667.

Retina: a unique subspecialty in the biosimilar landscape

Ashish Sharma, Nilesh Kumar, Nikulaa Parachuri, Carl D. Regillo, Francesco Bandello, Baruch D. Kuppermann

Eye (Lond) 2022 Jun; 36(6): 1145–1146. Published online 2022 Feb 21. doi: 10.1038/s41433-022-01984-w

PMCID:: PMC9151666

Article PDF–370K

Select item 89275748.

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study

Debdulal Chakraborty, Sabyasachi Sengupta, Soumen Mondal, Subhendu Boral, Arnab Das, Tushar Kanti Sinha, Ranabir Bhattacharya, Ritobroto Maitra

Ophthalmol Ther. 2022 Apr; 11(2): 629–638. Published online 2022 Jan 24. doi: 10.1007/s40123-022-00463-5

PMCID:: PMC8927574

Article PDF–518K

Select item 82165899.

Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World’s First Biosimilar Ranibizumab): A Comprehensive Review

Shashikant Sharma, Tanishq Sharma, Somdutt Prasad, Mahesh Gopalakrishnan, Alok Chaturvedi

Ophthalmol Ther. 2021 Sep; 10(3): 431–443. Published online 2021 Jun 21. doi: 10.1007/s40123-021-00362-1

PMCID:: PMC8216589

Article PDF–324K

Select item 807960010.

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases

Debdulal Chakraborty, Michael W. Stewart, Jay U. Sheth, Tushar K. Sinha, Subhendu Boral, Arnab Das, Soumen Mondal, Angshuman Mukherjee

Ophthalmol Ther. 2021 Jun; 10(2): 337–348. Published online 2021 Apr 17. doi: 10.1007/s40123-021-00345-2

PMCID:: PMC8079600

Article PDF–300K

Select item 793388511.

Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics

Giridhar Anantharaman

Indian J Ophthalmol. 2021 Feb; 69(2): 358–359. doi: 10.4103/ijo.IJO_40_21

PMCID:: PMC7933885

Article PDF–401K

Select item 793387712.

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns

Aman Kumar, Divya Agarwal, Atul Kumar

Indian J Ophthalmol. 2021 Feb; 69(2): 357–358. doi: 10.4103/ijo.IJO_39_21

PMCID:: PMC7933877

Article PDF–398K

Select item 793386313.

Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders

Sabyasachi Sengupta

Indian J Ophthalmol. 2021 Feb; 69(2): 209–210. doi: 10.4103/ijo.IJO_72_21

PMCID:: PMC7933863

Article PDF–509K

PMC

Result Filters

Article attributes

Text availability

Publication date

Custom date range

Research Funder

Additional filters

Display Settings:

Send to:

Links from PubMed

Items: 13

Display Settings:

Send to:

Supplemental Content

Find related data

Recent activity